Xcout IntelBELITE BIO, INC
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Subscribe to see BELITE BIO, INC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
BELITE BIO, INC at a glance
BELITE BIO, INC is a biotech company headquartered in San Diego, United States. It is publicly listed (BLTE) with a market capitalisation of $6.5B. Xcout tracks 14 named people at BELITE BIO, INC, including Dr Tom Lin (Chairman & CEO).
BELITE BIO, INC leadership
- Dr Tom LinChairman & CEO
- Yu-Hsin LinChairman of the Board of Directors & Chief Executive Officer
- Hao-Yuan ChuangChief Financial Officer & Director
- Hendrik SchollChief Medical Officer
- Kelly KilpatrickChief Commercial Officer
- Nathan L. MataChief Scientific Officer
8 more named people on record for BELITE BIO, INC, with roles, board committees and tenure — see the full roster →
BELITE BIO, INC competitors
A few of BELITE BIO, INC's closest competitors — see the full list of competitors and alternatives →
Lin BioScience is a clinical-stage biopharmaceutical company that discovers and develops novel, first-in-class drug candidates for the treatment of cancer, eye diseases, and metabolic diseases. The company serves patients with significant unmet medical needs through targeted therapies such as oral treatments for dry age-related macular degeneration, Stargardt disease, and acute leukemia.
SpliceBio is a clinical-stage genetic medicines company that develops gene therapies using a proprietary Protein Splicing platform. The company focuses on treating diseases caused by mutations in large genes, with a lead clinical program targeting Stargardt disease.
LifeCyte Innovations is a clinical-stage biopharmaceutical company that develops novel oral therapies targeting chronic inflammation to slow the progression of age-related degenerative conditions. Its primary product offering, RestoViz, is an investigational oral combination therapy designed to treat age-related macular degeneration (AMD) by reducing inflammation, oxidative stress, and drusen buildup, with additional clinical studies evaluating applications for mild cognitive impairment, Alzheimer's disease, and traumatic brain injury.
Stargazer Pharmaceuticals, Inc. is a Boston-based biopharmaceutical company focused on developing novel treatments for rare eye diseases, including Stargardt disease. The company advances clinical-stage pharmaceutical candidates through specialized clinical trials.
Beacon Therapeutics is a clinical-stage biotechnology company dedicated to saving and restoring sight for people living with rare and prevalent ocular diseases. The company works to deliver advanced retinal gene therapies to patients experiencing blindness.
Acucela is a biotechnology company developing ophthalmic therapeutics for retinal diseases, including age-related macular degeneration and Stargardt disease. Its research has included visual-cycle modulators such as emixustat, aimed at treating degenerative eye conditions.
Get BELITE BIO, INC's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on BELITE BIO, INC in Xcout Intel
- 14 named people with titles, LinkedIn and board committees
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access